The outside of Scripps Research, which would gain surer financial footing if ozanimod is approved.  Photo courtesy of Scripps

The outside of Scripps Research, which would gain surer financial footing if ozanimod is approved. Photo courtesy of Scripps

Scripps Research stands to gain a royalty windfall from a drug candidate that slows brain atrophy in patients with multiple sclerosis...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129